The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-25. Anything still debated is marked as such rather than presented as settled.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
A related concept is the 'bill of health', a document issued by officials of a port of departure indicating to the officials of the port of arrival whether it is likely that the ship is carrying a contagious disease, either literally on board as fomites or via its crewmen or passengers. As defined in a consul's handbook from 1879:
She befriends investor Jesse Bloom and secures him as a client by helping him seize control of healthcare startup Rican, undercutting Felim and contributing to Eric’s removal from the trading floor. Harper begins a relationship with new MD Daniel Van Deventer (DVD) and travels to Berlin to confront her estranged brother, who rebuffs her. When Pierpoint plans to fold London into New York, Harper engineers a survival bid with Eric to preserve a London office, getting DVD fired. After Jesse manipulates her into committing insider trading, Eric shields her by exposing her forged transcripts instead, getting her fired. In series 3, six weeks prior to the main events, Harper accompanies Yasmin on a cruise in Mallorca and helps cover up Charles Hanani’s drowning. In the present, Harper works at ethical fund FutureDawn, where she earns Petra Koenig’s trust during the tumultuous Lumi IPO by helping hedge her exposure; the two co-found their own firm, LeviathanAlpha, with backing from Otto Mostyn. Harper enlists Pierpoint as their broker to humiliate Eric and illegally plans a short of Pierpoint’s ESG-backed debt, using an unwitting Yasmin to obtain information. The betrayal damages their friendship. Harper ultimately abandons the short but partners with Otto months later to launch a new hedge fund focused on shorting corrupt firms they can control. She and Yasmin also reconcile. In series 4, Harper runs a short-only fund within Otto's asset management firm but grows frustrated with his tight oversight, later learning it is tied to his political interests.
S. mutilans, like other centipedes, is a predator that kills by injecting venom into its prey. Venom is injected to immobilize and break down internal tissues. Venoms of Scolopendridae, including Scolopendra mutilans, contain neurotoxins, which are suspected to be a significant fast-acting component in venoms of many centipedes. This species mainly feeds on live animals; plant materials are occasionally consumed but its consumption is considered negligible. To get hold of the prey, this centipede grabs prey with its anterior legs, and typically envenomates prey by stabbing it using its forcipules. Little quantitative ecological and behavioural work was done for centipedes. Some studies, however, have found that centipedes are highly selective and tend to strike at the head or thorax instead of the abdomen. If the bite was made on the abdomen, the centipede would usually reposition the prey and strike again on the head or thorax. Venom availability has a significant effect on predatory response. Returning to their normal attack rate after venom extraction takes more time when facing larger prey. Research on these behaviours has suggested that the reason for centipedes to reposition their prey is to enhance the speed where neurotoxins in the venom arrive at the thoracic ganglia, where it controls limb movement or the brain. This explanation was based on the position of such ganglia locating on the abdominal side (i.e.
=== RNAP sequencing === This method is based on use of RNA polymerase (RNAP), which is attached to a polystyrene bead. One end of DNA to be sequenced is attached to another bead, with both beads being placed in optical traps. RNAP motion during transcription brings the beads in closer and their relative distance changes, which can then be recorded at a single nucleotide resolution. The sequence is deduced based on the four readouts with lowered concentrations of each of the four nucleotide types, similarly to the Sanger method. A comparison is made between regions and sequence information is deduced by comparing the known sequence regions to the unknown sequence regions.
ATP is stable in aqueous solutions between pH 6.8 and 7.4 (in the absence of catalysts). At more extreme pH levels, it rapidly hydrolyses to ADP and phosphate. Living cells maintain the ratio of ATP to ADP at a point ten orders of magnitude from equilibrium, with ATP concentrations fivefold higher than the concentration of ADP. In the context of biochemical reactions, the P-O-P bonds are frequently referred to as high-energy bonds.
Sources: en.wikipedia.org
In the aftermath of World War II, the USAAF consolidated much of its wartime combat force and selected the P-51 as a "standard" piston-engined fighter, while other types, such as the P-38 and P-47, were withdrawn or given substantially reduced roles. As the more advanced (P-80 and P-84) jet fighters were introduced, the P-51 was also relegated to secondary duties. In 1947, the newly formed USAF Strategic Air Command employed fighter Mustangs alongside F-6 Mustangs and F-82 Twin Mustangs, due to their range capabilities. In 1948 a new designation scheme for USAF aircraft was introduced, with the prefix "P-" for "pursuit" changed to "F-" for "fighter" and the existing "F-" designation for photographic reconnaissance replaced with "RF-;" Mustang variants still in service in the USAF or Air National Guard (ANG) when the system was changed included: F-51B, F-51D, F-51K, RF-51D (formerly F-6D), RF-51K (formerly F-6K) and TRF-51D (two-seat trainer conversions of F-6Ds). By 1950, the majority of the USAF's Mustangs had become surplus to requirements and had been placed in storage or transferred to the Air Force Reserve and the ANG.
Tyrosine–tRNA ligase, cytoplasmic, also called Tyrosyl-tRNA synthetase 1, is an enzyme that in humans is encoded by the YARS1 gene (previously YARS). Like the mitochondrial variety, YARS2, this enzyme functions as a Tyrosine–tRNA ligase, meaning it functions to attach the amino acid tyrosine to its corresponding transfer RNA (tRNATyr) as part of RNA-to-protein translation.
Adedapo Segun (North West) Bello Rabiu (North West) Yusuf Usman (North East) Babs Omotowa (North Central), former Managing Director of Nigeria Liquefied Natural Gas Austin Avuru (South-South), Non-Executive Director David Ige (South-West) Henry Obih (South-East) Lydia Jafiya, Permanent Secretary of the Federal Ministry of Finance (Ministry’s representative) Aminu Ahmed (Ministry of Petroleum Resources representative) The Group Chief Executive Officer, Bayo Ojulari, has since resumed his duties and represented NNPCL at various official events, including an empowerment program for National Youth Service Corps (NYSC) members.
=== Beneficial === Beneficial nonsense mutations are considered as the rarest of possible nonsense mutation outcomes. Beneficial nonsense mutations increase the overall fitness and reproductive success of an organism, opposite of the effects of a deleterious mutation. Because a nonsense mutation introduces a premature stop codon within a sequence of DNA, it is extremely unlikely that this scenario can actually benefit the organism. An example of this would occur with a nonsense mutation that impacts a dysfunctional protein that releases toxins. The stop codon that this mutation brings would stop this dysfunctional protein from properly carrying out its function. Stopping this protein from performing at full strength causes less toxin to be released and the fitness of the organism to be improved. These types of situations with nonsense mutations occur a lot less frequently than the deleterious outcomes.
In 1958, scientists at Lawrence Berkeley National Laboratory claimed the discovery of element 102, now called nobelium. At the same time, they also tried to synthesize element 103 by bombarding the same curium target used with 14N ions. Eighteen tracks were noted, with decay energy around 9±1 MeV and half-life around 0.25 s; the Berkeley team noted that while the cause could be the production of an isotope of element 103, other possibilities could not be ruled out. While the data agrees reasonably with that later discovered for 257Lr (alpha decay energy 8.87 MeV, half-life 0.6 s), the evidence obtained in this experiment fell far short of the strength required to conclusively demonstrate synthesis of element 103. A follow-up on this experiment was not done, as the target was destroyed. Later, in 1960, the Lawrence Berkeley Laboratory attempted to synthesize the element by bombarding 252Cf with 10B and 11B. The results of this experiment were not conclusive. The first important work on element 103 was done at Berkeley by the nuclear-physics team of Albert Ghiorso, Torbjørn Sikkeland, Almon Larsh, Robert M. Latimer, and their co-workers on February 14, 1961. The first atoms of lawrencium were reportedly made by bombarding a three-milligram target consisting of three isotopes of californium with boron-10 and boron-11 nuclei from the Heavy Ion Linear Accelerator (HILAC). The Berkeley team reported that the isotope 257Lr was detected in this manner, and that it decayed by emitting an 8.6 MeV alpha particle with a half-life of 8±2 s.
Sources: en.wikipedia.org
== Psychoactive properties == Laussmann & Meier-Giebing (2010) reported the presence of psilocybin at ~2.5% and psilocin at ~1.194% from 25 samples seized by the German government, which makes modern commercially cultivated strains of this fungus the most potent hallucinogenic mushrooms ever described in published academic research. Other researchers have documented a significant presence of serotonin and urea in this species as well as the possibly psychoplastogenic indole alkaloid baeocystin.
Sir Henry Norris, the then Arsenal chairman, argued that Arsenal be promoted for their "long service to league football", having been the first League club from the South of England. It has been alleged that this was due to backroom deals and even outright bribery by Sir Henry Norris, colluding with his friend John McKenna, the chairman of Liverpool and the Football League, who recommended Arsenal's promotion at the AGM. No conclusive proof of wrongdoing has come to light, though other aspects of Norris's financial dealings unrelated to the promotion controversy have fuelled speculation on the matter. Norris resigned as chairman and left the club in 1929, having been found guilty by the Football Association of financial irregularities; he was found to have misused his expenses account, and to have pocketed the proceeds of the sale of the Arsenal team bus.
Lipofuscin accumulation in the eye is a major risk factor implicated in macular degeneration, a degenerative disease, and Stargardt disease, an inherited juvenile form of macular degeneration. In the peripheral nervous system, abnormal accumulation of lipofuscin known as lipofuscinosis is associated with a family of neurodegenerative disorders – neuronal ceroid lipofuscinoses, the most common of these is Batten disease. Also, pathological accumulation of lipofuscin is implicated in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, certain lysosomal diseases, acromegaly, denervation atrophy, lipid myopathy, chronic obstructive pulmonary disease, and centronuclear myopathy. Accumulation of lipofuscin in the colon is the cause of the condition melanosis coli. On the other hand, myocardial lipofuscin accumulation more directly reflects chronological ageing rather than human cardiac pathology.
According to López, the MTC benefited Chinese companies, principally the state-owned construction company China Civil Engineering Construction Corporation, which partnered with the company INIP Ingeniería Integración de Proyectos, the latter led by Roberto Aguilar Quispe, forming a partnership that won contracts between August 2021 and January 2022 worth 581 million soles. In August 2025, Attorney General Delia Espinoza presented a constitutional complaint before congress against Castillo and 24 congressmen, including those known as "Los Niños", for steering bids in favor of Chinese companies belonging to the so-called "Dragon Club".
Structural similarities between acetyl-CoA and malonyl-CoA suggest that certain lysine acetyltransferases (KATs) may also catalyze malonylation. KAT2A (GCN5) has been experimentally linked to histone malonylation and is currently the strongest candidate, while p300 has also been proposed and is known to mediate other acyl modifications such as crotonylation. Analogous to the GCN5 acetylation mechanism, the ε-amino group is thought to be transiently deprotonated by a catalytic base within the enzyme's active site, thereby enabling the same reaction with malonyl-CoA as in non-enzymatic malonylation. However, specific enzymes known as malonyltransferases have not yet been definitively identified. The demalonylation is catalyzed by the enzyme Sirtuin 5 (SIRT5), a class III histone deacetylase that requires NAD+ for activity but is inhibited by nicotinamide. SIRT5 is globally expressed in mitochondrial, cytoplasmic, and nuclear compartments, and can also remove other negatively charged acyl modifications. It catalyzes the demalonylation in the following reaction:
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.